Host immune rejection of TA3 ascites carcinoma cells following administration of a water soluble carbodiimide.
Regression of TA3 ascites carcinoma tumors occurred following i.p. injection of 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide-HC1. An immunological mechanism of drug action was indicated by the fact that no significant antitumor activity was demonstrable in mice that had previously received an immunosuppressive 700 rad dose of 60Co radiation.
D000818:Animals; D001201:Ascites; D002234:Carbodiimides / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D002460:Cell Line; D003037:Cobalt Radioisotopes; D005022:Ethyldimethylaminopropyl Carbodiimide / Q000627:therapeutic use*; D006084:Graft Rejection; D007165:Immunosuppression Therapy; D051379:Mice; D009368:Neoplasm Transplantation
D002234:Carbodiimides; D003037:Cobalt Radioisotopes; D005022:Ethyldimethylaminopropyl Carbodiimide